Recent models capturing the pathophysiology of sepsis and ex-vivo data from patients are speculating about immunosuppression in the so-called late phase of sepsis. Clinical data regarding survival and microbiological burden are missing. Gordon P. Otto, of the Clinic for Anesthesiology and Intensive Care at Jena University Hospital inJena, Germany, and colleagues, sought to determine the clinical significance of the 'late phase' of sepsis with respect to overall survival and occurrence of microbiological findings.
In a retrospective trial, 16,041 patient charts from a university intensive care unit were screened, and 999 patients with severe sepsis or septic shock were identified. Three phases were established according to the mortality peaks which were separated by two distinct nadirs: phase I (days 1-5), phase II (days 6-15) and phase III (days 16-150). Patients were analyzed for outcome, SOFA Scores, procalcitonin levels, antimicrobial treatment, dialysis, mechanical ventilation and results of blood cultures during their hospital stay.
Out of 999 enrolled patients, 308 died during the course of sepsis presenting a characteristic mortality rate (30.8 percent) with three distinct mortality peaks (at the days 2,7 and 17). Overall 36.7 percent of all deaths occurred in the early phase (phase I) and 63.3 percent during the later phases (phase II+III). In total, 2,117 blood cultures were drawn. In phase I, 882 blood cultures were drawn, representing a sampling rate of 88 percent with a positive rate of 14.9 percent. In phase II, 461 samples were taken, indicating a sampling rate of 52 percent and a positive rate of 11.3 percent. Within phase III, 524 samples were obtained representing a sampling rate of 66 percent with a positive rate of 15.3 percent, which was significantly higher compared to the positive rate of phase II and similar to phase I. In particular, the rate of typically opportunistic bacteria increased significantly from 9 percent in phase I up to 18 percent in phase III. The same is true for Candida spp. (phase I 13 percent, phase III 30 percent).
The researchers conclude that the later phase of sepsis is associated with a significant re-increase of positive blood culture results, especially regarding opportunistic bacteria and fungi. They add that these observations warrant further studies focusing on the underlying mechanisms resulting in this outcome burden in the later phase of sepsis. Their research was published in Critical CAre 2011.
Reference: Otto GP, Sossdorf M and Claus RA, et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Critical Care 2011, 15:R183doi:10.1186/cc10332
Happy Hand Hygiene Day! Rethinking Glove Use for Safer, Cleaner, and More Ethical Health Care
May 5th 2025Despite their protective role, gloves are often misused in health care settings—undermining hand hygiene, risking patient safety, and worsening environmental impact. Alexandra Peters, PhD, points out that this misuse deserves urgent attention, especially today, World Hand Hygiene Day.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.